New class of antigen-specific cancer immunotherapy
based on an off-the-shelf antigen presenting cell line

News

PDCline Pharma presents first clinical results from Phase I/II trial with PDClung01 at ESMO 2022

2022-09

PDC*line Pharma presents first clinical results from Phase I/II trial with PDC*lung01 at ESMO 2022

Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and

Read more about PDC*line Pharma presents first clinical results from Phase I/II trial with PDC*lung01 at ESMO 2022

PDC*line Pharma will be presenting a poster at the ESMO Annual Meeting 2022

2022-09

We are thrilled to announce that PDC*line Pharma will be presenting a poster at the ESMO - European Society for Medical Oncology Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. The poster will highlight clinical

Read more about PDC*line Pharma will be presenting a poster at the ESMO Annual Meeting 2022

WE ARE HIRING A QUALITY ASSURANCE AND LOGISTICS ASSISTANT

2022-07

PDC*line Pharma is hiring a Quality Assurance and Logistics Assistant in Belgium. Are you interested to join an international dynamic team in the biotech cancer vaccine space? Be part of the adventure and join us!

See enclosed the Job Description: Q

Read more about WE ARE HIRING A QUALITY ASSURANCE AND LOGISTICS ASSISTANT

WE ARE HIRING A QUALITY CONTROL TECHNICIAN IN BELGIUM

2022-06

PDC*line Pharma is #hiring a Quality Control Technician in Belgium. Are you interested to join an international dynamic team in the biotech cancer vaccine space? Be part of the adventure and join us!

See enclosed the Job Description. QC technician

Read more about WE ARE HIRING A QUALITY CONTROL TECHNICIAN IN BELGIUM

We are hiring a Senior Production Supervisor / Production Technician

2022-05

PDC*line Pharma is hiring a Senior Production Supervisor / Production Technician in Belgium. Are you interested to join an international dynamic team in the biotech cancer vaccine space?

Be part of the adventure and join us!

See enclosed the Job

Read more about We are hiring a Senior Production Supervisor / Production Technician

linkedin twitter

PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).

About us

A first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages

Potent & effective

Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

Scalable & convenient

Simple production of a large quantity of a highly qualified off-the-shelf product

Versatile & applicable to any cancers

The peptides can easily be changed to target a specific cancer type

Management Team

Eric Halioua

Laurent Levy

Dr. Joel Plumas

Claude DEDRY

Dr. Channa Debruyne

Candidate products

Melanoma

Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

Melanoma is often easier to detect in its early stages than most cancers. However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Despite new treatments, prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

Read more about PDC mel

Lung Cancer

Lung cancer is the most common malignancy worldwide for male patients and for both sexes combined (2.1 million new cases per year), and the third most common for female patients (after breast and colorectal cancers). Deaths from lung cancer exceed those from any other malignancy globally, with the number of lung-cancer-related deaths worldwide for 2018 estimated at 1.8 million (Globocan 2018), representing 18.4% for both sexes. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

Read more about Lung Cancer

Technology

PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.

About our technology